FDA Inspection
Piedmont Reproductive Endocrinology Group, PAPiedmont Reproductive Endocrinology Group, PA – FDA Inspection, Jan 9, 2026
Record Details
This FDA Inspection record concerns Piedmont Reproductive Endocrinology Group, PA, with an inspection on January 9, 2026, issued by the Atlanta District Office, covering biologics.
- Inspection Date
- January 9, 2026
- Product Type
- Biologics
View Company Profile
ID · a2c79c9a-3be3-4b19-99db-18b5584e0af2
Inspection Facts
- Inspection number
- 1298188
- FDA center
- Biologics
- Project area
- Human Cellular, Tissue, and Gene Therapies
- Outcome
- Form 483 issued
FDA Citations
2- 21 CFR 1271.47(a)Testing, screening, donor eligibility procedures
- 21 CFR 1271.75(e)Abbreviated procedure
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Piedmont Reproductive Endocrinology Group, PA
3| Date | Classification | Office | Project area |
|---|---|---|---|
| November 1, 2022 | NAI | Center for Biologics Evaluation and Research | Vaccines and Allergenic Products |
| May 21, 2019 | NAI | Center for Biologics Evaluation and Research | Blood and Blood Products |
| June 27, 2017 | NAI | Center for Biologics Evaluation and Research | Human Cellular, Tissue, and Gene Therapies |
Other documents for Piedmont Reproductive Endocrinology Group, PA
- FDA Inspection 1187380 - 2022-11-01
- FDA Inspection 1091218 - 2019-05-21
- FDA Inspection 1016583 - 2017-06-27
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.